Compare LEG & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEG | GPCR |
|---|---|---|
| Founded | 1883 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2023 |
| Metric | LEG | GPCR |
|---|---|---|
| Price | $11.26 | $34.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.00 | ★ $69.57 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $4,172,899,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $13.22 |
| 52 Week High | $12.30 | $40.29 |
| Indicator | LEG | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 54.98 |
| Support Level | $11.26 | $30.94 |
| Resistance Level | $12.03 | $36.09 |
| Average True Range (ATR) | 0.38 | 2.50 |
| MACD | 0.23 | -0.48 |
| Stochastic Oscillator | 77.00 | 41.07 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.